Table 1 Insulin versus hypoglycaemic drugs
From: Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
Studies | Methodological quality: Low/moderate/good (Blinding Yes/No) | Participants (Ins/C) | TreatmentsTreatments | Follow-up (weeks) | Inclusion criteria | Primary outcome |
|---|---|---|---|---|---|---|
Alvarsson 2009 [32] | Moderate (No) | 51 (23/28) | Insulin/glibenclamide | 104 | FBG: [6; 12 mmol/L] 35–75 years | HbA1c, metabolic control |
Aschner 2012 [33] | Good (No) | 515 (250/265) | Met/S + Insulin Glargine/Sitagliptin | 24 | [7 %; 11] 35–70 years BMI = [25–45 kg/m2] | HbA1c |
Bunck 2009 [34] | Moderate (No) | 69 (33/36) | Met + Insulin glargine/exenatide | 52 | [6,5 %; 9,5] 35–75 years BMI = [25–40 kg/m2] | Metabolic control |
Davies 2009 [35] | Good (No) | 233 (117/118) | OHD (Met/S/TZD) + Insulin glargine/exenatide | 51 | [7,5 %;10 %] BMI > 27 kg/m2 | HbA1c |
Diamant 2010 [36] | Moderate (No) | 467 (234/233) | OHD (Met/Met-S) + Insulin glargine/exenatide | 26 | [7 %; 11 %] - BMI : [25-40 kg/m2] | HbA1C |
Gallwitz 2011 [37] | Moderate (No) | 363 (181/182) | Met + Insulin Aspart/exenatide | 26 | [6,5 %; 10] | HbA1c |
Gerstein 2006 [38] | Moderate (No) | 405 (206/199) | OHD + Insulin glargine/conventional | 24 | [7,5 %; 11 %] BMI: [21–41 kg/m2] 18–80 years | HbA1c |
Gerstein 2012 [39] | Good (No) | 12527 (6273/6264) | Lifestyle recommendations and OHD + Glargine/Conventional care/omega3/placebo | 6 years | Recent diabetes/Glucose Intolerance/ | Composite of CV events |
Hartemann 2011 [40] | Moderate (No) | 27 (13/14) | OHD (Met/S) + Insulin NPH/Pioglitazone | 24 | [7,5 %; 9,5 %] BMI > 26 kg/m2 18–80 years | HbA1c |
Heine 2009 [41] | Moderate (No) | 551 (267/282) | OHD (Met/S) + Insulin Glargine/Exenatide | 26 | [7 %; 10 %] BMI: [25–45 kg/m2] 35–75 years | HbA1c |
Hollander 2009 [42] | Moderate (No) | 217 (107/110) | OHD (Met + Sitagliptin) + Insulin Detemir/+/− S | 26 | [7,5 %; 10 %] BMI < 40 kg/m2 | HbA1c |
Nauck 2007 [43] | Moderate (No) | 501 (248/253) | OHD (Met/S) + Insulin Aspart/Exenatide | 52 | [7 %; 11 %] BMI : [25–40 kg/m2] 30–75 years | HbA1c |
Nauck 2012 [44] | Good (No) | 1037 (364/351/322) | Met + S + Taspoglutide 10/taspoglutide 20/Insulin Glargine | 24 | [7 %; 10 %] BMI : [25–45 kg/m2] 18–75 ans | HbA1c |
Reynolds 2007 [45] | Moderate (No) | 40 (20/20) | OHD (Met/S) + Insulin Aspart/Rosiglitazone | 26 | [8 %; 12 %] | HbA1c, metabolic control |
Rosenstock 2006 [46] | Good (No) | 217 (105/112) | OHD (Met/S) + Insulin Glargine/Rosiglitazone | 24 | [7,5 %; 11 %] BMI > 25 kg/m2 >18 years | HbA1c |
UKPDS 24 1998 [47] | Good (No) | 458 (178/231/49) | Insulin/Chlorpropamide or Glyburide/Metformin | 6 years | Diet failure UKPDS 33 25–60 years | HbA1c/FPG |